Health Condition 1: null- patients with intracranial tumour and patients posted for spinal cord procedures (no intracranial pathology)
Conditions
Interventions
Intervention1: Dexmedetomidine: Dexmedetomidine (1 microgram/Kg) will be given over 10 minutes to patients without intracranial tumours ( spine surgeries) and static autoregulation will be assessed
Co
Sponsors
Sri Chitra Tirunal Institute for Medical Science and Technology
Eligibility
Inclusion criteria
Inclusion criteria: Two groups of patients will be included (10 patients in each group) • Group I â?? patient with unilateral supra tentorial tumours • Group II â?? patients with no intra cranial pathology (lumbar spinal cord procedures) Inclusion criteria: •Patients categorized as American society of Anesthesiology (ASA) class 1 and 2. •Age 18-40 years. •Glasgow coma scale 15. •patients with unilateral tumour in supratentorial compartment like glioma and meningioma (GroupI) •Patients posted for lumbar spinal cord procedures including laminectomy, discectomy and spinal cord tumour excision (Group II)
Exclusion criteria
Exclusion criteria: • Patient refusal • American society of Anesthesiology (ASA) class III and above • Age less than 18 years and more than 40 years. • Emergency surgery • Presence of intracranial vascular abnormalities ( Aneurysm, Arterio venous malformation) • Known allergy to Dexmedetomidine or any α2 agonists. • Known allergy to Inj. Phenylephrine • Preoperative heart rate • Systemic hypertension stage III & above • Antihypertensive medication with α-methyldopa or Clonidine. • Patient on beta blockers • Presence of Coronary artery disease, Left ventricular dysfunction, • Pregnant or Nursing woman. • Abnormal temporal bone window for transcranial Doppler insonation • Difficulty in localizing intracranial vasculature by Transcranial color Doppler • Participation in another drug study during the preceding 1 month period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| static cerebral vascular autoregulationTimepoint: 1. Baseline and 2.After administration of Dexmedetomidine (10 minutes after baseline) | — |
Secondary
| Measure | Time frame |
|---|---|
| mean flow velocity of middle cerebral artery and Pulsatility index, cerebral perfusion pressure derived from flow velocity data.Timepoint: 1. baseline 2.after dexmedetomine (1mcg/kg over 10 minutes) | — |
Countries
India
Contacts
Public ContactARULVELAN
Sri Chitra Tirunal Institute for Medical Science and Technology
Outcome results
None listed